News

Neurosense Therapeutics said it’s scaled production of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS), to commercial levels as it awaits regulatory approval to launch the medication in Canada. “This manufacturing milestone represents a critical leap forward in our commercialization roadmap,” Alon Ben-Noon, CEO of Neurosense, said in…

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. ATLX-1282 was developed using Alchemab’s platform, which uses machine learning and artificial intelligence (AI) to identify potential therapeutic targets for diseases…

Crunch Fitness will host a nationwide fundraising event to support Augie’s Quest to Cure ALS, an organization dedicated to funding innovative research, help develop treatments, and raise awareness of amyotrophic lateral sclerosis (ALS). Both Crunch members and nonmembers may take part at Crunch locations nationwide on May…

Implanting a sensor in a region of the brain that helps to control speech was shown in a U.S. study to not only decode the intended speech of a man with amyotrophic lateral sclerosis (ALS), but also to help this patient control a computer mouse. According to the researchers,…

Note: This story was updated May 13, 2025, to correct information about the company’s clinical trials. Spinogenix has received clearance from the U.S. Food and Drug Administration (FDA) to launch an expanded access program (EAP) for SPG302, its oral treatment for amyotrophic lateral sclerosis (ALS). EAPs, also known…

The real-world use of Radicava (edaravone), an infusion treatment approved for amyotrophic lateral sclerosis (ALS), may cause serious side effects — such as liver problems, blood clots, pain, brain bleeding, and infection — not previously listed in its label, according to data from the U.S. drug regulatory agency’s…

Prilenia Therapeutics has entered a collaboration and license agreement with Ferrer to codevelop and commercialize pridopidine, its therapy candidate for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), in Europe and other select markets. The partnership comes as pridopidine nears an expected regulatory decision in the European Union, where…

ALS groups are asking lawmakers to preserve federal funding for the National ALS Registry and National ALS Biorepository, the first and only comprehensive nationwide resource to collect and analyze data for better understanding amyotrophic lateral sclerosis (ALS). “A recently leaked draft memo from the U.S. Department of Health and…

Across the U.S. and around the world, the amyotrophic lateral sclerosis (ALS) community is aiming to raise its voice in powerful ways this May during awareness month  — with advocacy campaigns, flag displays, the sharing of personal stories, and community-led events. ALS Awareness Month, according to supporters of those…

Arizona-based Brad Smith has become the first person with amyotrophic lateral sclerosis (ALS) to receive a brain implant from Neuralink as part of an ongoing clinical trial. The implant, which is designed to allow users to control a computer using only their thoughts, has granted Smith newfound independence…